Navigation Links
Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment
Date:4/16/2008

ROCHESTER, Minn., April 16, 2008 /PRNewswire-USNewswire/ -- A new Mayo Clinic study found that regular physical exercise may help protect against mild cognitive impairment, a disorder of the brain that affects nerve cells involved in thinking abilities. This study will be presented at the American Academy of Neurology Annual Meeting in Chicago on April 16.

Individuals with mild cognitive impairment can function reasonably well in everyday activities, but often have difficulty remembering details of conversations, events and upcoming appointments. Most (but not all) patients with mild cognitive impairment develop a progressive decline in their thinking abilities over time. Alzheimer's disease is usually the underlying cause.

"While the benefits of exercise are well documented for improving overall health, this is one of the first studies to specifically look at whether it can help protect against the development of mild cognitive impairment," says Yonas Endale Geda, M.D., a Mayo Clinic neuropsychiatrist and the study's lead investigator.

As part of the ongoing Mayo Clinic Study of Aging, Dr. Geda and a team of Mayo Clinic researchers randomly identified 868 individuals 70 to 89 years old. Of those, 128 had mild cognitive impairment and 740 were cognitively normal. The team conducted surveys to gather data on the individuals' physical exercise between the ages of 50 and 65 and one year prior to the survey. They found that moderate physical exercise two to five times per week during the ages of 50 to 65 was associated with a reduced risk of mild cognitive impairment. However, the individual's exercise habits one year prior to the survey did not appear to be associated with a reduced risk.

According to Dr. Geda, these findings need to be replicated in a prospective cohort study. Additionally, the study did not address how physical exercise could protect against mild cognitive impairment.

"Regarding the mechanism of act
'/>"/>

SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2008)...INGAPORE, Aug. 15 /- AstraZ...new partnership with the National Cancer,Centre Si...l (NUH) to,develop anti-cancer compounds. The coll...nderstanding (MOU) that was signed today, aims to ...ilities in Asia and ultimately,speed up access to ...
(Date:8/14/2008)...st T cell engaging antibody (BiTE) showing clinica... patients own T cells to recognize and attack ...Md., Aug. 14 /- Micromet, I...developing novel, proprietary,antibodies for the t...seases, today announced publication of a Phase 1 c...
(Date:8/14/2008)... - Phase 2 development to begin in late 2008 or i...wswire-FirstCall/ -- Nuvelo, Inc.,(Nasdaq: NUVO )...b,proof-of-concept trial of NU172, demonstrating t... and maintained anticoagulation with a rapid,retur...favorable safety,profile., "NU172 has the potenti...
(Date:8/13/2008)...igh Omega-3 Fat Intake Improves Insulin Sensitivit...lter Endocrine Responsiveness, PHOENIX, Aug. 13 /...enix-based Kronos Longevity Research Institute (KL... insulin sensitivity and reduces inflammatory,mark...This study was,recently published in Hormones and ...
Breaking Medicine Technology:AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4Study Shows Benefits of a High Omega-3 Diet in Older Adults 2Study Shows Benefits of a High Omega-3 Diet in Older Adults 3Biophysical Society announces winners of 2008 Minority Travel Awards 1714 1Biophysical Society announces winners of 2008 Minority Travel Awards 1714 2Kids in Poor Neighborhoods Fall Behind in School 8726 1Kids in Poor Neighborhoods Fall Behind in School 8726 2Songbirds offer clues to highly practiced motor skills in humans 8724 1Songbirds offer clues to highly practiced motor skills in humans 8724 2Songbirds offer clues to highly practiced motor skills in humans 8724 3Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America 8720 1Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America 8720 2
.../ -- A new Harris Poll,suggests that the flu vacci...ctive than the vaccines used in some previous year... were only 24 percent,less likely to get the flu t... were larger in two previous Harris Polls on the s.../2005 adults who were,vaccinated were 33 percent a...
...udy showed significant,results in favor of alemtuz...., May 02, 2007,/PRNewswire-FirstCall/ -- Genzyme ...day announced detailed interim results from the,CA... patient data,through at least twenty-four months ...d that a once-yearly cycle of alemtuzumab,treatmen...
Other Medicine Technology:Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 2Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 3Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 4Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 5Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 7Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 8Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 9
(Date:8/20/2008)...WTON, Mass., Aug. 20 /PRNewswire/ -- Questex Media...siness media company and owner of,American Spa and... the,International Beauty Shows, the International...d the SPATEC appointment events today announced th... portals SpaTrade (, http://www.SpaTrade.com ) an...
(Date:8/20/2008)...r in secondary life insurance market ranked 156 am...in America on Inc. 500 list, BETHESDA, Md., Aug. ...der in the secondary life insurance market, announ...growing insurance related company in the US by,Inc... 2008 Inc. 500 list of,fastest growing companies i...
(Date:8/20/2008)...UTHFIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/... Wellness Promotion will give thousands of,Detroit..."HEALTHY LIVING,FOR KIDS" program. This year the p...0 a.m. to 5 p.m. at the Charles H. Wright Museum o... 1977, "Healthy Living for Kids",has provided free...
(Date:8/20/2008)...LWAUKEE, Aug. 20 /PRNewswire/ -- Fourteen physicia...p have announced that they plan to enhance,the car...ining Aurora,Health Care., "These are top-notch p...have decided to join our organization," said Nick ...ve officer. "We look forward to working with,them ...
Breaking Medicine News(10 mins):Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:Integrity Capital Partners Ranked 2nd Fastest Growing Insurance Related Company in US by Inc. Magazine 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2
...ucted by drug researchers has revealed that enabli...ates who are addicted to heroin, //would serve a d...nce and the cost of locking up prisoners for a yea...l Health and Medical Research Council sponsored th...
...ugh a study by neuroscientists at Harvard Medical ...-term exposure to stress hormone in mice directly ...ssion. // April issue of Behavioral Neuroscience, ...chological Association, has this article. This wo...
...es on headline-grabbing diseases, hemophilia, a li...silent killer with over 50,000 people affected. //... to promote a global effort to secure appropriate ...is the oldest known inherited bleeding disorder ca...
...e the promising field of stem cell technology furt...g study //that intends to verify the virtue, succe... a cure for heart disease. Experiments will be c... heart patients. This study will be a fusion of ef...
Other Medicine News:Health News:Cost-Benefit Economics of Methadone for prisoners 2
...r is a multi-lumen, over-the-wire thrombectomy cat...al of fresh, soft thrombus in dialysis shunts. The...y alternative to surgery and thrombolytic therapy....jector. Fragments and removes thrombus to help re...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system.
...tomy catheter is designed to offer the ultimate in...eate a low pressure zone around the catheter tip c... catheter, where it is fragmented by the jets, and...vides rapid restoration of flow in minutes, as opp...
When combined with a stimulation lead system, the Model 3077 SSI Temporary Pacemaker can be used whenever temporary atrial or ventricular pacing is indicated. The device can be employed for therapeut
Medicine Products: